Sign in
CompletedPhase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya, and Uganda6 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
52 people enrolled
Started
23 Jan 2024
Ended
21 Feb 2025
Type of study
Interventional, 4 groups
Treatments tested
  • INE963
Record updated
19 November 2025

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Male and female patients ≥18 years of age at screening
  • Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 5,000 to 150,000 asexual parasite count/μl of blood for P. falciparum
  • Patients must weigh between 40 kg and 90 kg
  • Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours

Who cannot take part

  • Patients with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
  • Any known/suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening
  • Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level < 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
  • Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:; AST/ALT > 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin; AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN; Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
  • History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:; Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker; History of familial long QT syndrome or known family history of Torsades de Pointe; Resting heart rate (physical exam or 12 lead ECG) < 50 bpm; Other protocol-defined inclusion/exclusion criteria may apply
  • Pregnant or nursing (lactating) women, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective contraception, and sexually active patients not willing to practice effective contraception

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.

The 4 groups in the trial

  • Cohort A1: INE963 Dose Level 1Treatment being tested

    Treatment: INE963

  • Cohort A1: INE963 Dose Level 2Treatment being tested

    Treatment: INE963

  • Cohort A1: INE963 Dose Level 3Treatment being tested

    Treatment: INE963

  • Cohort A1: INE963 Dose Level 4Treatment being tested

    Treatment: INE963

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria
Record updated
19 November 2025